VolitionRX (NYSEAMERICAN:VNRX) is a clinical diagnostics company focused on developing and commercializing simple, blood‐based tests for the detection and diagnosis of cancer and other diseases. The company applies proprietary epigenetic technology to identify changes in nucleosomes circulating in the bloodstream, offering a minimally invasive alternative to traditional biopsy methods. By targeting a broad range of malignancies, VolitionRX aims to facilitate early disease detection, improve patient outcomes and reduce the costs associated with late‐stage cancer treatment.
The company’s flagship product line, marketed under the Nu.Q® brand, includes assays designed to detect colorectal, prostate, liver and other cancers in various clinical settings. These assays measure specific epigenetic markers on nucleosomes to distinguish between healthy and diseased states. VolitionRX’s research and development pipeline also features next-generation tests for multi-cancer screening, as well as applications in transplant medicine and inflammatory diseases. Strategic collaborations with academic institutions and healthcare providers help advance test validation and broaden clinical adoption.
VolitionRX was founded in 2009 as a spin-out from research conducted at Ghent University in Belgium. The company maintains its global headquarters in Nivelles, Belgium, and operates a subsidiary in the United States to oversee regulatory affairs, clinical trials and commercialization efforts across North America. In addition to its European and U.S. presence, VolitionRX has established partnerships in Asia, the Middle East and Latin America to support pilot programs and expand access to its diagnostic tests in emerging markets.
The leadership team at VolitionRX brings together professionals with extensive experience in biotechnology, diagnostics and regulatory affairs. The board and executive officers include seasoned executives who have guided companies through clinical validation, regulatory approval and commercial launch of life-science products. Under this management structure, VolitionRX continues to advance its mission of delivering accessible, accurate and cost-effective diagnostics to healthcare systems worldwide.
AI Generated. May Contain Errors.
Free VNRX Stock Alerts